middle.news
Race Oncology Advances Phase 1 Trial, Boosts Cash to $18.8M with New Board Appointments
6:31pm on Sunday 1st of June, 2025 AEST
•
Biopharmaceutical
Read Story
Race Oncology Advances Phase 1 Trial, Boosts Cash to $18.8M with New Board Appointments
6:31pm on Sunday 1st of June, 2025 AEST
Key Points
Phase 1 trial ethics submission for RC220 completed, first patient expected Q1 2025
Cash reserves increased to $18.78 million after $5.25 million R&D tax incentive
New board appointment: Dr Megan Baldwin joins as independent Non-Executive Director
Two senior scientists, Dr Kirsten Curnow and Dr Sumit Sahni, added to R&D team
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE